Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UCB-MNCs for Refractory Immune Effector Cell-related Hemocytopenia
NCT06729320Not yet recruiting
- Sponsor
- Beijing Gaobo Hospital
- Start
- Dec 2024
- Primary completion
- Jun 2025
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Randomised, open-label trial of umbilical cord blood mononuclear cells in immune effector cell-associated cytopenia (ICA-cytopenia) (2 arms), sponsored by Beijing Gaobo Hospital. Primary endpoints: The recovery time of neutrophils at 1 year, The recovery time of platelet at 1 year and 1 more. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
umbilical cord blood mononuclear cells
03
Conditions
immune effector cell-associated cytopenia (ICA-cytopenia)
Beyond the preview
Go deeper on NCT06729320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06729320.